Vulvovaginitis treatment options
Pro Research Analysisby 
Searched over 200M research papers
Common Causes and Diagnosis of Vulvovaginitis
Vulvovaginitis is a frequent condition in women and girls, caused by infections such as vulvovaginal candidiasis (VVC), bacterial vaginosis (BV), trichomoniasis, and less commonly, aerobic vaginitis or desquamative inflammatory vaginitis. Diagnosis should be based on clinical symptoms and laboratory confirmation, as symptoms alone cannot reliably distinguish between causes. In recurrent or complicated cases, further testing like fungal culture and species identification is recommended, while serological tests are not useful for VVC diagnosis Farr2021Kumar2024Zuckerman2016.
Standard Antifungal and Antimicrobial Treatments
For acute VVC, local antifungal agents such as imidazoles, polyenes, or ciclopirox olamine (in the form of vaginal tablets, ovules, or creams) are effective. Oral triazoles can also be used, sometimes in combination with topical antifungal creams for vulvar involvement. These treatments are generally well tolerated and show similar efficacy. For BV, standard treatments include metronidazole and clindamycin Farr2021Reef1995Kumar2024.
In pregnancy, local (topical) antifungal treatment is preferred to minimize systemic exposure. For recurrent VVC, maintenance therapy with oral triazoles is recommended, and for non-albicans Candida infections, alternative antifungal agents should be considered Farr2021Reef1995Kumar2024.
Boric Acid and Novel Antiseptic Options
Boric acid has emerged as a promising alternative, especially for recurrent or resistant cases of VVC and BV. Studies show an average cure rate of 76% for VVC with boric acid, and it is also effective for recurrent BV and some cases of trichomoniasis. Maintenance regimens with boric acid are comparable to oral itraconazole for preventing recurrences. Adverse events are usually mild and temporary Müller2024Kumar2024Marrazzo2018.
A novel boric acid-based vaginal anti-infective, TOL-463, has shown high cure rates for both BV and VVC, particularly in vaginal insert form, and is well tolerated. This product may help disrupt biofilms that contribute to treatment resistance and recurrence .
Dequalinium Chloride and Other Antiseptics
Dequalinium chloride (DQC) is a local antiseptic with broad antimicrobial and antifungal activity. It has demonstrated non-inferiority to standard treatments for BV, VVC, and aerobic vaginitis, with good safety and tolerability. However, it is not yet widely recommended as a first-line treatment pending further research .
Alternative and Complementary Therapies
There is growing interest in alternative and complementary therapies for vulvovaginitis, especially for VVC. These include natural substances like propolis, garlic, tea tree oil, and vinegar, which may have antifungal or microbiota-restoring properties. However, some of these products can cause side effects and lack robust clinical trial evidence. Their use should be approached with caution .
Addressing Azole-Resistant and Recurrent Infections
Azole-resistant Candida species present a significant challenge, as treatment options are limited. Fluconazole resistance is increasing due to overuse, and new antifungal drug classes are needed. For now, alternative agents like boric acid and non-azole antifungals are used for refractory cases, but more research and new therapies are urgently needed Chew2016Sobel2018Müller2024.
Management in Special Populations
In prepubertal and adolescent females, treatment should include hygiene counseling and targeted therapy for identified pathogens. Partner therapy and follow-up testing are important to prevent reinfection, especially in sexually transmitted infections like Chlamydia trachomatis Kumar2024Zuckerman2016.
Conclusion
Treatment options for vulvovaginitis are diverse and depend on the underlying cause. Standard antifungal and antimicrobial agents remain effective for most cases, while boric acid and dequalinium chloride offer promising alternatives for recurrent or resistant infections. Alternative therapies are being explored but require more evidence. Addressing drug resistance and recurrence remains a key challenge, highlighting the need for ongoing research and individualized patient care Eckel2023Felix2018Farr2021+7 MORE.
Sources and full results
Most relevant research papers on this topic
Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
Current antimycotic treatments for Vulvovaginal candidosis face challenges, and novel therapeutic and prophylactic options are needed to combat complications and improve patient quality of life.
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
New therapeutic options and strategies are urgently needed for women with azole-resistant vulvovaginal candidiasis, as current treatments are limited and azole resistance is on the rise.
Boric Acid for the Treatment of Vaginitis: New Possibilities Using an Old Anti‐Infective Agent: A Systematic Review
Boric acid is an effective treatment option for microbial vaginitis, with an average cure rate of 76% for vulvovaginal candidiasis and promising results for recurrent bacterial vaginosis.
Treatment options for vulvovaginal candidiasis, 1993.
Topical and oral antifungal agents are effective for treating acute episodes of vulvovaginal candidiasis in nonpregnant women, while low-dose oral ketoconazole is effective for recurrent cases.
DOI